Caplin Point Laboratories has received approval from the United States Food and Drug Administration (USFDA) for its Milrinone injection, a critical cardiovascular therapy used to manage heart failure and related conditions. The approval allows the Indian pharmaceutical company to market the injectable formulation in the U.S., a key market for high-value generic injectables. This milestone strengthens Caplin Point’s cardiovascular portfolio and underscores its capabilities in producing complex formulations for regulated markets.